360biolabs

We are passionate about using cutting-edge thinking and technology to support the development of therapeutics, vaccines and diagnostics.

360biolabs supports the first Australian COVID-19 clinical vaccine trials

28 April 2020

In one of the first COVID-19 clinical vaccine trials, US-based clinical-stage biotechnology company Novavax (NASDAQ: NVAX) has selected Australian speciality laboratory 360biolabs, to conduct sample analysis for the clinical trial of its SARS-CoV-2 recombinant spike protein nanoparticle vaccine, NVX-CoV2373.

Due to the nature and sensitivities of certain assays used in this clinical trial, a specialist biosecurity facility is required. With its highly experienced scientists working in state of the art Biosafety Level 2 (BSL-2) and 3 (BSL-3) laboratories, 360biolabs has the ideal resources and environment to conduct these crucial studies.

As Australia’s only ISO accredited, clinical services organisation, currently working with SARS-CoV-2, 360biolabs have received global requests for antiviral testing and clinical trial support. 360biolabs’ wealth of knowledge in the respiratory virus antiviral discovery and clinical space, ensures the team will delivery high quality, robust and reliable data.

Read more

Introducing 360biolabs

360biolabs is Australia’s most comprehensive speciality laboratory services organisation for therapeutic, vaccine and diagnostics development. We develop and conduct pharmacokinetic (PK) and pharmacodynamic (PD) assays across a wide variety of therapeutic areas and provide extensive support services to ensure the success of preclinical studies and clinical trials.

We are passionate about using cutting-edge thinking and technology to support the development of therapeutics, vaccines and diagnostics.

360biolabs has cutting-edge laboratory facilities at Burnet Institute, perfectly situated to benefit from the unique advantages of conducting studies in Australia.

Visit 360biolabs.com for more information.

Virology

We offer world-leading capabilities to test and characterise antivirals, biological agents, vaccines and diagnostics. Our team has experience with a broad range of viruses and we possess an extensive curated library including clinical isolates.

Immunology

Highly specialised immunoassay service supporting the development of vaccines and immunotherapies.

IND-enabling services

ICH / FDA /EMA compliant packages ensuring a defined pathway to IND Data and formal reports in accordance with the FDA’s “Guidance for Industry” Industry standard reporting formats and customisation to clients’ requirements.

Clinical services

Our experienced team provides expert assistance for the support of clinical trials.

Assay suite includes:

  • ELISA
  • ELISpot assays
  • Neutralisation assays
  • Flow cytometry
  • Multiplex assay
  • Phagocytic function and oxidative burst activity analysis
  • Qualitative and quantitative culture
  • Quantitative PCR
  • Resistance monitoring
  • Reverse genetics
  • Production of in vitro transcripts for assay quantitation and validation

Other services include:

  • Bio-banking
  • Stability studies
  • Clinical sample logistics

Access

360biolabs is located at Burnet Institute, 85 Commercial Rd, Melbourne.

Contact Details

For any general enquiries relating to this facility, please contact:

Associate Professor David Anderson

Deputy Director (Partnerships), Burnet Institute; Co-Head, Global Health Diagnostics Development

Telephone

+61392822239

Email

david.anderson@burnet.edu.au